Fundz
New|Fundz now works inside Claude2 min

Discover more near‑term opportunities with better event intelligence.

Fundz combines its own real-time funding and M&A intelligence with executive moves, hiring shifts and other company changes, weighs each signal against your ideal customer profile, and delivers a ranked daily shortlist with the context and decision maker to contact. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.

Trusted by

OracleSnowflakeCloudflareLinkedInGoogleSalesforce
4.8/5 on G2· Since 2015

R1 Therapeutics expands Series A financing to $80.5 million with new investment from Samsara BioCapital. The funds will advance their Phase 2b program for hyperphosphatemia in patients with chronic kidney disease.

PRIVATESep 30, 2026

Amount Raised

$80.5 Million

Round Type

Series A

BiotechnologyHealth CareTherapeutics

Investors

U.S. Renal CareSNMA CapitalCurie.BioF PrimeDaVita Venture GroupAbingworthSamsara Biocapital

Description

R1 Therapeutics, a biopharmaceutical company focused on kidney disease therapies, has expanded its Series A financing to $80.5 million. This expansion includes new investment from Samsara BioCapital, joining other notable investors. The raised funds will support the development of R1's lead asset, AP306, in a global Phase 2b trial. The trial aims to address hyperphosphatemia in patients on dialysis, with topline data expected in early 2027.

Company Information

Company

R1 Therapeutics

About

R1 Therapeutics is a biotechnology company focused on developing innovative therapeutics. The company leverages advanced technologies to create treatments that address unmet medical needs. Their approach aims to enhance patient outcomes and streamline the drug development process. With a commitment to scientific excellence, R1 Therapeutics strives to bring novel therapies to market.

Fundz sees it the moment R1 Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for R1 Therapeutics's next move

See what Strategic adds

Funding Insights

What this usually means
Typical timeline to Series B
Series A companies typically raise their next round in 10-18 months

R1 Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.